Parkinsonism & Related Disorders
Volume 16, Issue 7 , Pages 458-465 , August 2010

A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias

  • Christopher A. Lieu

      Affiliations

    • Department of Neurology, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • Department of Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • ,
  • Allen R. Kunselman

      Affiliations

    • Department of Public Health Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • ,
  • Bala V. Manyam

      Affiliations

    • Department of Neurology, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • ,
  • Kala Venkiteswaran

      Affiliations

    • Department of Neurology, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • Department of Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • ,
  • Thyagarajan Subramanian

      Affiliations

    • Department of Neurology, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • Department of Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • Corresponding Author InformationCorresponding author at: H109, Neurology and Neural & Behavioral Sciences, Penn State University Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA. Tel.: +1 717 531 0003x283767; fax: +1 717 531 0996.

Received 27 August 2009 ,Revised 6 April 2010 ,Accepted 29 April 2010.

References 

  1. Deogaonkar M, Subramanian T. Pathophysiological basis of drug-induced dyskinesias in Parkinson’s disease. Brain Res Brain Res Rev. 2005;50:156–168
  2. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(Suppl. 1):S9–S15
  3. Manyam BV, Sanchez-Ramos JR. Traditional and complementary therapies in Parkinson’s disease. Adv Neurol. 1999;80:565–574
  4. Manyam BV. Paralysis agitans and levodopa in “Ayurveda”: ancient Indian medical treatise. Mov Disord. 1990;5:47–48
  5. Vaidya RA, Aloorkar SD, Sheth AR, Pandya SK. Activity of bromoergocryptine, Mucuna pruriens and L-dopa in the control of hyperprolactinaemia. Neurol India. 1978;26:179–182
  6. Damodaran M, Ramaswamy R. Isolation of l-3:4-dihydroxyphenylalanine from the seeds of Mucuna pruriens. Biochem J. 1937;31:2149–2152
  7. Bell EA, Janzen DH. Medical and ecological considerations of L-dopa and 5-HTP in seeds. Nature. 1971;229:136–137
  8. Mahajani SS, Doshi VJ, Parikh KM, Manyam BV. Bioavailability of L-DOPA from HP-200-a formulation of seed powder of Mucuna pruriens (Bak): a pharmacokinetic and pharmacodynamic study. Phytother Res. 1996;10:254–256
  9. Modi KP, Patel NM, Goyal RK. Estimation of L-dopa from Mucuna pruriens LINN and formulations containing M. pruriens by HPTLC method. Chem Pharm Bull (Tokyo). 2008;56:357–359
  10. Pras N, Woerdenbag HJ, Batterman S, Visser JF, Van Uden W. Mucuna pruriens: improvement of the biotechnological production of the anti-Parkinson drug L-dopa by plant cell selection. Pharm World Sci. 1993;15:263–268
  11. Vaidya RA, Sheth AR, Aloorkar SD, Rege NR, Bagadia VN, Devi PK, et al. The inhibitory effect of the cowhage plant-Mucuna pruriens-and L-dopa on chlorpromazine-induced hyperprolactinaemia in man. Neurol India. 1978;26:177–178
  12. Kasture S, Pontis S, Pinna A, Schintu N, Spina L, Longoni R, et al. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson’s disease. Neurotox Res. 2009;15:111–122
  13. Hussian G, Manyam BV. Mucuna pruriens proves more effective than L-DOPA in Parkinson’s disease animal model. Phytother Res. 1997;11:419–423
  14. Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75:1672–1677
  15. Subramanian T, Marchionini D, Potter EM, Cornfeldt ML. Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant. 2002;11:207–214
  16. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci. 1995;15:3863–3875
  17. Schallert T. Behavioral tests for preclinical intervention assessment. NeuroRx. 2006;3:497–504
  18. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000;39:777–787
  19. Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci. 1995;15:5372–5378
  20. Warraich ST, Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, et al. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Res Bull. 2009;78:85–90
  21. Steece-Collier K, Collier TJ, Danielson PD, Kurlan R, Yurek DM, Sladek JR. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov Disord. 2003;18:1442–1454
  22. Steece-Collier K, Soderstrom KE, Collier TJ, Sortwell CE, Maries-Lad E. Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J Comp Neurol. 2009;515:15–30
  23. McLean IW, Nakane PK. Periodate–lysine–paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem. 1974;22:1077–1083
  24. Subramanian T, Emerich DF, Bakay RA, Hoffman JM, Goodman MM, Shoup TM, et al. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant. 1997;6:469–477
  25. Manyam BV, Dhanasekaran M, Hare TA. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res. 2004;18:97–101
  26. An alternative medicine treatment for Parkinson’s disease: results of a multicenter clinical trial. HP-200 in Parkinson’s Disease Study Group. J Altern Complement Med. 1995;1:249–255
  27. Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP. Association of L-DOPA with recovery following Ayurveda medication in Parkinson’s disease. J Neurol Sci. 2000;176:124–127
  28. Vaidya AB, Rajagopalan TG, Mankodi NA, Antarkar DS, Tathed PS, Purohit AV, et al. Treatment of Parkinson’s disease with the cowhage plant-Mucuna pruriens Bak. Neurol India. 1978;26:171–176
  29. Goetze O, Nikodem AB, Wiezcorek J, Banasch M, Przuntek H, Mueller T, et al. Predictors of gastric emptying in Parkinson’s disease. Neurogastroenterol Motil. 2006;18:369–375

☆ The review of this paper was entirely handled by an Associate Editor, Robert Rodnitzky.

PII: S1353-8020(10)00104-5

doi: 10.1016/j.parkreldis.2010.04.015

Parkinsonism & Related Disorders
Volume 16, Issue 7 , Pages 458-465 , August 2010

Article Tools

* Image Usage & Resolution